NCT01631864View on ClinicalTrials.gov

Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
HypertensionConcurrent Obesity
Interventions
DRUG

LCZ696

LCZ696 was provided as 400 mg tablets.

DRUG

amlodipine

amlodipine was provided as 5 mg tablets.

DRUG

Placebo

Matching placebo to LCZ696 and amlodipine.

Trial Locations (3)

5800

Novartis Investigative Site, Maastricht

30625

Novartis Investigative Site, Hanover

41460

Novartis Investigative Site, Neuss

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY